NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2025, along with recent ...
The Hearty Soul on MSN
New Vitamin-Based Compound Could Restore Brain Function Lost to Alzheimer's
Around 10 million new cases of dementia are diagnosed globally every year, with Alzheimer’s disease accounting for 60-70% of ...
Liver disease, a significant health concern, progresses from potentially reversible fibrosis to irreversible cirrhosis. While ...
A multidisciplinary research team has discovered that liver alterations associated with metabolic dysfunction–associated ...
At-home tests of the gut's microbiome are trending, but doctors say the technology is getting ahead of medical knowledge.
News-Medical.Net on MSN
How artificial light interferes with liver health
People who work against their internal clock over a long period of time increase the risk of fatty liver. The correlations are complex, but one research team in Bochum is trying to get to the bottom ...
2don MSN
Can your daily tea harm your liver? Study and expert explain when and how much is safe to drink
Your daily cup of tea might be impacting your liver more than you think. Research suggests moderate consumption, especially ...
Experiencing shortness of breath when walking even short distances can be concerning. While deconditioning or anxiety can ...
Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, ...
Servier today announced that VORANIGO® (vorasidenib) has been awarded The Galien Foundation's 2025 Prix Galien USA ...
Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback